Your browser is no longer supported. Please, upgrade your browser.
Beam Therapeutics Inc.
Index- P/E- EPS (ttm)-4.10 Insider Own1.80% Shs Outstand56.62M Perf Week-8.51%
Market Cap4.14B Forward P/E- EPS next Y-3.22 Insider Trans-9.44% Shs Float48.66M Perf Month-10.59%
Income-195.90M PEG- EPS next Q-0.74 Inst Own72.90% Short Float13.52% Perf Quarter-38.39%
Sales0.02M P/S172522.53 EPS this Y-108.70% Inst Trans2.19% Short Ratio6.14 Perf Half Y81.10%
Book/sh4.34 P/B15.41 EPS next Y-6.60% ROA-57.90% Target Price104.71 Perf Year235.24%
Cash/sh4.84 P/C13.82 EPS next 5Y- ROE-83.50% 52W Range18.76 - 126.90 Perf YTD-18.08%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-46.08% Beta-
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low264.77% ATR6.41
Employees181 Current Ratio3.00 Sales Q/Q0.00% Oper. Margin- RSI (14)41.48 Volatility12.98% 8.71%
OptionableYes Debt/Eq0.03 EPS Q/Q-145.60% Profit Margin- Rel Volume1.04 Prev Close66.88
ShortableYes LT Debt/Eq0.02 EarningsMay 11 BMO Payout- Avg Volume1.07M Price68.43
Recom2.10 SMA20-7.44% SMA50-13.28% SMA20011.84% Volume260,866 Change2.32%
May-11-21Initiated Redburn Buy
May-04-21Initiated RBC Capital Mkts Sector Perform $85
Mar-01-21Downgrade Barclays Overweight → Equal Weight $47 → $90
Feb-16-21Initiated Wells Fargo Overweight $145
Jan-29-21Downgrade JP Morgan Overweight → Neutral $100
Jan-06-21Initiated Stifel Hold $84
Aug-05-20Initiated William Blair Outperform
Mar-02-20Initiated Wedbush Outperform $32
Mar-02-20Initiated JP Morgan Overweight $31
Mar-02-20Initiated Jefferies Buy $32
Mar-02-20Initiated Barclays Overweight $32
May-11-21 12:28PM  
May-04-21 03:00PM  
Apr-30-21 01:31PM  
Apr-27-21 04:41PM  
Apr-20-21 10:12AM  
Apr-17-21 06:01AM  
Mar-28-21 11:11PM  
Mar-15-21 06:30AM  
Mar-04-21 06:30AM  
Feb-23-21 04:19PM  
Feb-16-21 01:36PM  
Feb-05-21 08:58AM  
Jan-19-21 06:30AM  
Jan-15-21 06:12PM  
Jan-14-21 03:11PM  
Jan-11-21 06:30AM  
Jan-07-21 04:24PM  
Jan-06-21 11:00AM  
Jan-05-21 06:30AM  
Dec-24-20 11:10AM  
Dec-10-20 10:02AM  
Dec-07-20 05:19PM  
Dec-05-20 07:00AM  
Nov-20-20 04:01PM  
Nov-13-20 08:00AM  
Nov-10-20 06:30AM  
Nov-09-20 08:15AM  
Nov-02-20 06:06AM  
Oct-07-20 10:04AM  
Oct-02-20 08:00AM  
Sep-28-20 04:18PM  
Aug-12-20 06:30AM  
Aug-04-20 07:15AM  
Jul-30-20 06:30AM  
Jun-15-20 06:00AM  
May-26-20 06:30AM  
May-18-20 06:21PM  
May-12-20 01:40PM  
May-06-20 10:25AM  
Apr-28-20 04:35PM  
Mar-30-20 06:30AM  
Mar-16-20 07:00AM  
Mar-05-20 01:53PM  
Feb-11-20 07:41AM  
Feb-05-20 07:05PM  
Jan-27-20 07:24AM  
Jan-25-20 05:00AM  
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Evans John M.CEOApr 23Option Exercise1.036,0006,1801,021,429Apr 23 04:45 PM
Evans John M.CEOApr 21Sale70.4925,0001,762,2161,015,429Apr 23 04:45 PM
Ciaramella GiuseppePresident & CSOMar 05Option Exercise0.674,0302,70019,761Apr 02 05:13 PM
Burrell Terry-AnnCFOJan 04Option Exercise13.6825,000342,00032,309Jan 05 05:40 PM
Burrell Terry-AnnCFOJan 04Sale81.7825,0002,044,4857,309Jan 05 05:40 PM
Ciaramella GiuseppePresident & CSODec 30Option Exercise0.9555,84253,19747,573Jan 04 05:32 PM
Ciaramella GiuseppePresident & CSODec 30Sale83.2643,8423,650,1443,731Jan 04 05:32 PM
Evans John M.CEODec 30Sale84.9422,3001,894,125970,957Jan 04 05:31 PM
Ciaramella GiuseppePresident & CSOSep 30Option Exercise0.673,7312,5003,731Oct 02 05:49 PM
Burrell Terry-AnnCFOSep 18Option Exercise13.687,30999,9877,309Sep 21 09:08 PM